RedHill Biopharma (RDHL) Return on Sales (2016 - 2024)
Historic Return on Sales for RedHill Biopharma (RDHL) over the last 13 years, with Q4 2024 value amounting to 32.81%.
- RedHill Biopharma's Return on Sales rose 338200.0% to 32.81% in Q4 2024 from the same period last year, while for Dec 2024 it was 32.81%, marking a year-over-year increase of 338200.0%. This contributed to the annual value of 1.82% for FY2024, which is 54800.0% down from last year.
- Per RedHill Biopharma's latest filing, its Return on Sales stood at 32.81% for Q4 2024, which was up 338200.0% from 9.45% recorded in Q2 2024.
- RedHill Biopharma's 5-year Return on Sales high stood at 32.81% for Q2 2023, and its period low was 6.58% during Q4 2021.
- Its 5-year average for Return on Sales is 4.67%, with a median of 0.62% in 2021.
- Within the past 5 years, the most significant YoY rise in RedHill Biopharma's Return on Sales was 338200bps (2024), while the steepest drop was -233500bps (2024).
- Quarter analysis of 5 years shows RedHill Biopharma's Return on Sales stood at 0.7% in 2020, then crashed by -1036bps to 6.58% in 2021, then grew by 17bps to 5.43% in 2022, then soared by 81bps to 1.02% in 2023, then surged by 3323bps to 32.81% in 2024.
- Its Return on Sales stands at 32.81% for Q4 2024, versus 9.45% for Q2 2024 and 1.02% for Q4 2023.